Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1-(4-cyclohexylureidophenoxy)-2-hydroxy-3-tert-butylaminopropane
2. Cordanum
3. Talinolol Acetate
4. Talinolol Benzoate
5. Talinolol Hydrochloride
6. Talinolol Monoacetate
7. Talinolol Monohydrochloride
8. Talinolol Mononitrate
9. Talinolol Monosalicylate
10. Talinolol Nitrate
11. Talinolol Oxalate
12. Talinolol Oxalate (2:1)
13. Talinolol Salicylate
14. Talinolol Sulfate
15. Talinolol Sulfate (2:1)
16. Talinolol Tartrate (2:1), L-(+)-isomer
17. Talinolol Tartrate, L-(+)-isomer
18. Talinolol, (+-)-isomer
1. 57460-41-0
2. Cordanum
3. 1-(4-(3-(tert-butylamino)-2-hydroxypropoxy)phenyl)-3-cyclohexylurea
4. Talinolol [inn]
5. 38649-73-9
6. Cordanum; Racemic Talinolol
7. 1-{4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-3-cyclohexylurea
8. 1-[4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-3-cyclohexylurea
9. 3s82268bkg
10. Talinolol (inn)
11. Racemic Talinolol
12. ( Inverted Exclamation Marka)-talinolol
13. Ncgc00164542-01
14. Dsstox_cid_26426
15. Dsstox_rid_81604
16. Dsstox_gsid_46426
17. (+-)-talinolol
18. Talinololum
19. Rac Talinolol
20. Talinololum [inn-latin]
21. Cas-57460-41-0
22. (+/-)-talinolol
23. Unii-3s82268bkg
24. 1-(4-cyclohexylureidophenoxy)-2-hydroxy-3-tert-butylaminopropane
25. (+-)-n-cyclohexyl-n'-(4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)urea
26. 1-(4-(cyclohexylureido)phenoxy)-3-(tert-butylamino)-2-propanol
27. Talinolol [mi]
28. 1-(3-(3-cyclohexylureido)phenoxy)-3-(tert-butylamino)-2-propanol
29. Talinolol [mart.]
30. Talinolol [who-dd]
31. Schembl78047
32. Chembl152067
33. Gtpl4664
34. Dtxsid6046426
35. Chebi:135533
36. Bcp30483
37. Tox21_112171
38. Bdbm50502344
39. (+-)-1-(p-(3-(tert-butylamino)-2-hydroxypropoxy)phenyl)-3-cyclohexylurea
40. Akos003382147
41. Tox21_112171_1
42. At33613
43. Db11770
44. (+-)-1-(4-(3-(tert-butylamino)-2-hydroxypropoxy)phenyl)-3-cyclohexylharnstoff
45. Urea, N-cyclohexyl-n'-(4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)-, (+-)-
46. Ncgc00164542-02
47. Db-072303
48. Ft-0674796
49. D07184
50. Sr-01000945249
51. Q7679533
52. Sr-01000945249-1
53. F1905-6534
54. N-cyclohexyl-n'-[4-(3-tert-butylamino-2-hydroxypropoxy)phenyl]urea
55. 3-{4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-1-cyclohexylurea
56. N-{4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-n'-cyclohexylurea
57. N-{4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-n'-cyclohexylcarbamimidic Acid
Molecular Weight | 363.5 g/mol |
---|---|
Molecular Formula | C20H33N3O3 |
XLogP3 | 2.6 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 8 |
Exact Mass | 363.25219192 g/mol |
Monoisotopic Mass | 363.25219192 g/mol |
Topological Polar Surface Area | 82.6 Ų |
Heavy Atom Count | 26 |
Formal Charge | 0 |
Complexity | 411 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Anti-Arrhythmia Agents
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)
Adrenergic beta-Antagonists
Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
C - Cardiovascular system
C07 - Beta blocking agents
C07A - Beta blocking agents
C07AB - Beta blocking agents, selective
C07AB13 - Talinolol
ABOUT THIS PAGE
A Talinolol manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Talinolol, including repackagers and relabelers. The FDA regulates Talinolol manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Talinolol API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Talinolol supplier is an individual or a company that provides Talinolol active pharmaceutical ingredient (API) or Talinolol finished formulations upon request. The Talinolol suppliers may include Talinolol API manufacturers, exporters, distributors and traders.
click here to find a list of Talinolol suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Talinolol written confirmation (Talinolol WC) is an official document issued by a regulatory agency to a Talinolol manufacturer, verifying that the manufacturing facility of a Talinolol active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Talinolol APIs or Talinolol finished pharmaceutical products to another nation, regulatory agencies frequently require a Talinolol WC (written confirmation) as part of the regulatory process.
click here to find a list of Talinolol suppliers with Written Confirmation (WC) on PharmaCompass.
Talinolol Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Talinolol GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Talinolol GMP manufacturer or Talinolol GMP API supplier for your needs.
A Talinolol CoA (Certificate of Analysis) is a formal document that attests to Talinolol's compliance with Talinolol specifications and serves as a tool for batch-level quality control.
Talinolol CoA mostly includes findings from lab analyses of a specific batch. For each Talinolol CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Talinolol may be tested according to a variety of international standards, such as European Pharmacopoeia (Talinolol EP), Talinolol JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Talinolol USP).
LOOKING FOR A SUPPLIER?